PD1 and LAG3 receptor expression were measured on the CD8+ T cells, while PDL1 (a PD1 ligand) and HLA-DP, DQ, and DR (LAG3 ligands) were chosen as the target ligands on cancer cells. Here, CD8A is linked to cancer.